Jüngst D, Büll U, Karl H J
Klin Wochenschr. 1982 May 3;60(9):477-8. doi: 10.1007/BF01720363.
In 17 patients with compensated autonomous adenomas of the thyroid, iv thyrotropin releasing hormone (TRH) tests (200 microgram) and oral TRH tests (40 mg) were performed. In nine of these patients, thyroid-stimulating hormone (TSH) 30 min after iv TRH showed a normal (greater than 2.7 microU/ml) and in eight patients a subnormal (less than 2.7 microU/ml) or negative response. However, after prolonged oral stimulation with 40 mg TRH, after 120-180 min TSH was normal (greater than 2.7 microU/ml) in 15 and subnormal (less than 2.7 microU/ml) in two patients. In 20 patients with decompensated autonomous thyroid nodules. TSH was not detectable (less than 0.8 microU/ml) after iv or oral TRH stimulation. Therefore, the oral TRH stimulation test seemed to be superior to the iv TRH test in the discrimination of compensated and decompensated autonomous adenomas of the thyroid.
对17例甲状腺自主性腺瘤代偿期患者进行了静脉注射促甲状腺激素释放激素(TRH)试验(200微克)和口服TRH试验(40毫克)。其中9例患者静脉注射TRH后30分钟促甲状腺激素(TSH)显示正常(大于2.7微单位/毫升),8例患者反应低于正常(小于2.7微单位/毫升)或呈阴性。然而,在用40毫克TRH进行长时间口服刺激后,120 - 180分钟时,15例患者的TSH正常(大于2.7微单位/毫升),2例患者低于正常(小于2.7微单位/毫升)。在20例甲状腺自主性结节失代偿期患者中,静脉注射或口服TRH刺激后TSH均检测不到(小于0.8微单位/毫升)。因此,在鉴别甲状腺代偿性和失代偿性自主性腺瘤方面,口服TRH刺激试验似乎优于静脉注射TRH试验。